

# Dmitriy Zamarin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2439342/publications.pdf>

Version: 2024-02-01

97  
papers

8,563  
citations

87888

38  
h-index

56724

83  
g-index

102  
all docs

102  
docs citations

102  
times ranked

12655  
citing authors

#	ARTICLE	IF	CITATIONS
1	TOX is a critical regulator of tumour-specific T cell differentiation. <i>Nature</i> , 2019, 571, 270-274.	27.8	697
2	Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. , 2020, 8, e000337.		610
3	Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy. <i>Science Translational Medicine</i> , 2014, 6, 226ra32.	12.4	590
4	Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. <i>Journal of Experimental Medicine</i> , 2013, 210, 1389-1402.	8.5	562
5	Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner. <i>Cell Reports</i> , 2015, 13, 412-424.	6.4	387
6	Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient. <i>Cell</i> , 2017, 170, 927-938.e20.	28.9	368
7	A Single Amino Acid Substitution in 1918 Influenza Virus Hemagglutinin Changes Receptor Binding Specificity. <i>Journal of Virology</i> , 2005, 79, 11533-11536.	3.4	356
8	Influenza Virus PB1-F2 Protein Induces Cell Death through Mitochondrial ANT3 and VDAC1. <i>PLoS Pathogens</i> , 2005, 1, e4.	4.7	306
9	Influenza A Virus PB1-F2 Protein Contributes to Viral Pathogenesis in Mice. <i>Journal of Virology</i> , 2006, 80, 7976-7983.	3.4	276
10	IRE1 $\alpha$ -XBP1 controls T cell function in ovarian cancer by regulating mitochondrial activity. <i>Nature</i> , 2018, 562, 423-428.	27.8	252
11	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. <i>Cell</i> , 2022, 185, 563-575.e11.	28.9	223
12	Attenuation of Equine Influenza Viruses through Truncations of the NS1 Protein. <i>Journal of Virology</i> , 2005, 79, 8431-8439.	3.4	220
13	Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 1814-1823.	1.6	202
14	Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine. <i>Nature Communications</i> , 2020, 11, 4011.	12.8	198
15	Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions. <i>Future Microbiology</i> , 2012, 7, 347-367.	2.0	185
16	Nuclear Localization of the Nipah Virus W Protein Allows for Inhibition of both Virus- and Toll-Like Receptor 3-Triggered Signaling Pathways. <i>Journal of Virology</i> , 2005, 79, 6078-6088.	3.4	174
17	Unraveling tumor-immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy. <i>Nature Genetics</i> , 2020, 52, 582-593.	21.4	136
18	Pharmacologic modulation of RNA splicing enhances anti-tumor immunity. <i>Cell</i> , 2021, 184, 4032-4047.e31.	28.9	131

#	ARTICLE	IF	CITATIONS
19	Immune-Active Microenvironment in Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Rationale for Immune Checkpoint Blockade. <i>Journal of the National Cancer Institute</i> , 2018, 110, 787-790.	6.3	123
20	Oncolytic Specificity of Newcastle Disease Virus Is Mediated by Selectivity for Apoptosis-Resistant Cells. <i>Journal of Virology</i> , 2011, 85, 6015-6023.	3.4	119
21	Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors. <i>EBioMedicine</i> , 2016, 6, 50-58.	6.1	113
22	PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy. <i>Journal of Clinical Investigation</i> , 2018, 128, 1413-1428.	8.2	111
23	Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity. <i>Nature Communications</i> , 2017, 8, 14340.	12.8	110
24	Pre-existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy. <i>Molecular Therapy</i> , 2018, 26, 1008-1019.	8.2	103
25	Intratumoral delivery of inactivated modified vaccinia virus Ankara (iMVA) induces systemic antitumor immunity via STING and Batf3-dependent dendritic cells. <i>Science Immunology</i> , 2017, 2, .	11.9	101
26	Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 5939-5947.	7.0	100
27	Tim-4+ cavity-resident macrophages impair anti-tumor CD8+ TĀcell immunity. <i>Cancer Cell</i> , 2021, 39, 973-988.e9.	16.8	93
28	Differential IL-10R1 Expression Plays a Critical Role in IL-10-Mediated Immune Regulation. <i>Journal of Immunology</i> , 2001, 167, 6884-6892.	0.8	85
29	Enhancement of Oncolytic Properties of Recombinant Newcastle Disease Virus Through Antagonism of Cellular Innate Immune Responses. <i>Molecular Therapy</i> , 2009, 17, 697-706.	8.2	84
30	Multimodal data integration using machine learning improves risk stratification of high-grade serous ovarian cancer. <i>Nature Cancer</i> , 2022, 3, 723-733.	13.2	82
31	Immune checkpoint modulation: Rational design of combination strategies. , 2015, 150, 23-32.		76
32	Pan-cancer Analysis of CDK12 Alterations Identifies a Subset of Prostate Cancers with Distinct Genomic and Clinical Characteristics. <i>European Urology</i> , 2020, 78, 671-679.	1.9	72
33	Tumor Immunity and Immunotherapy for HPV-Related Cancers. <i>Cancer Discovery</i> , 2021, 11, 1896-1912.	9.4	71
34	Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer. , 2020, 8, e001126.		54
35	Newcastle Disease Virus at the Forefront of Cancer Immunotherapy. <i>Cancers</i> , 2020, 12, 3552.	3.7	53
36	Antitumor efficacy of viral therapy using genetically engineered Newcastle disease virus [NDV(F3aa)-GFP] for peritoneally disseminated gastric cancer. <i>Journal of Molecular Medicine</i> , 2010, 88, 589-596.	3.9	49

#	ARTICLE	IF	CITATIONS
37	Role of Immunotherapy in the Management of Locally Advanced and Recurrent/Metastatic Cervical Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 91-97.	4.9	47
38	Mogamulizumab in Combination with Durvalumab or Tremelimumab in Patients with Advanced Solid Tumors: A Phase I Study. <i>Clinical Cancer Research</i> , 2020, 26, 4531-4541.	7.0	46
39	Combination Immune Checkpoint Blockade Strategies to Maximize Immune Response in Gynecological Cancers. <i>Current Oncology Reports</i> , 2018, 20, 94.	4.0	43
40	Carcinoma-Associated Mesenchymal Stem Cells Promote Chemoresistance in Ovarian Cancer Stem Cells via PDGF Signaling. <i>Cancers</i> , 2020, 12, 2063.	3.7	43
41	The New Era of Cancer Immunotherapy. <i>Advances in Cancer Research</i> , 2015, 128, 1-68.	5.0	41
42	Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients. , 2020, 8, e001153.		37
43	Machine learning-based prediction of microsatellite instability and high tumor mutation burden from contrast-enhanced computed tomography in endometrial cancers. <i>Scientific Reports</i> , 2020, 10, 17769.	3.3	35
44	Identification of recurrent FHL2-GLI2 oncogenic fusion in sclerosing stromal tumors of the ovary. <i>Nature Communications</i> , 2020, 11, 44.	12.8	34
45	Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial. , 2020, 8, e000829.		34
46	Genetically Engineered Oncolytic Newcastle Disease Virus Effectively Induces Sustained Remission of Malignant Pleural Mesothelioma. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 2761-2769.	4.1	33
47	Therapeutic effects of a fusogenic newcastle disease virus in treating head and neck cancer. <i>Head and Neck</i> , 2011, 33, 1394-1399.	2.0	33
48	Potential of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer. <i>Molecular Therapy - Oncolytics</i> , 2014, 1, 14004.	4.4	33
49	Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade. <i>Gynecologic Oncology</i> , 2019, 152, 251-258.	1.4	33
50	Immunotherapy and radiation therapy sequencing: State of the data on timing, efficacy, and safety. <i>Cancer</i> , 2021, 127, 1553-1567.	4.1	33
51	Senescence induction dictates response to chemo- and immunotherapy in preclinical models of ovarian cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	7.1	33
52	Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade. , 2022, 10, e004076.		30
53	Functional landscapes of POLE and POLD1 mutations in checkpoint blockade-dependent antitumor immunity. <i>Nature Genetics</i> , 2022, 54, 996-1012.	21.4	30
54	<i>BRCA</i> Mutations, Homologous DNA Repair Deficiency, Tumor Mutational Burden, and Response to Immune Checkpoint Inhibition in Recurrent Ovarian Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 665-679.	3.0	29

#	ARTICLE	IF	CITATIONS
55	Lysis-independent potentiation of immune checkpoint blockade by oncolytic virus. <i>Oncotarget</i> , 2018, 9, 28702-28716.	1.8	27
56	Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine. <i>Gynecologic Oncology</i> , 2016, 141, 86-94.	1.4	26
57	Harnessing the immune system for cancer therapy. <i>Current Opinion in Oncology</i> , 2014, 26, 600-607.	2.4	25
58	A phase II trial of durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial carcinoma and endometrial carcinosarcoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 5582-5582.	1.6	25
59	Tumor-Derived Lysophosphatidic Acid Blunts Protective Type I Interferon Responses in Ovarian Cancer. <i>Cancer Discovery</i> , 2022, 12, 1904-1921.	9.4	25
60	Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 701-704.	2.5	24
61	Fundamental immune“oncogenicity trade-offs define driver mutation fitness. <i>Nature</i> , 2022, 606, 172-179.	27.8	23
62	Adjuvant chemotherapy in patients with operable granulosa cell tumors of the ovary: a surveillance, epidemiology, and end results cohort study. <i>Cancer Medicine</i> , 2018, 7, 2280-2287.	2.8	21
63	Replication-Competent Viruses as Cancer Immunotherapeutics: Emerging Clinical Data. <i>Human Gene Therapy</i> , 2015, 26, 538-549.	2.7	19
64	Targeting galectin-3 with a high-affinity antibody for inhibition of high-grade serous ovarian cancer and other MUC16/CA-125-expressing malignancies. <i>Scientific Reports</i> , 2021, 11, 3718.	3.3	18
65	Computed Tomography“Derived Radiomic Metrics Can Identify Responders to Immunotherapy in Ovarian Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-13.	3.0	16
66	Genetic and molecular subtype heterogeneity in newly diagnosed early- and advanced-stage endometrial cancer. <i>Gynecologic Oncology</i> , 2021, 161, 535-544.	1.4	16
67	Design and Production of Newcastle Disease Virus for Intratumoral Immunomodulation. <i>Methods in Molecular Biology</i> , 2020, 2058, 133-154.	0.9	15
68	Subsequent therapies and survival after immunotherapy in recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2019, 155, 51-57.	1.4	14
69	Geometric network analysis provides prognostic information in patients with high grade serous carcinoma of the ovary treated with immune checkpoint inhibitors. <i>Npj Genomic Medicine</i> , 2021, 6, 99.	3.8	13
70	Detection of Free Peritoneal Cancer Cells in Gastric Cancer Using Cancer-Specific Newcastle Disease Virus. <i>Journal of Gastrointestinal Surgery</i> , 2010, 14, 7-14.	1.7	11
71	Preparation of single cells from tumors for single-cell RNA sequencing. <i>Methods in Enzymology</i> , 2020, 632, 295-308.	1.0	11
72	A phase I open-label study of selinexor with paclitaxel and carboplatin in patients with advanced ovarian or endometrial cancers. <i>Gynecologic Oncology</i> , 2021, 160, 71-76.	1.4	9

#	ARTICLE	IF	CITATIONS
73	Expanding Our Impact in Cervical Cancer Treatment: Novel Immunotherapies, Radiation Innovations, and Consideration of Rare Histologies. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2021, 41, 252-263.	3.8	8
74	Molecular characterization of high-grade serous ovarian cancers occurring in younger and older women. Gynecologic Oncology, 2021, 161, 545-552.	1.4	8
75	Recommendations for Testing and Treating Outpatient Cancer Patients in the Era of COVID-19. Journal of the National Cancer Institute, 2021, 113, 820-822.	6.3	7
76	Polyclonal IgA Gammopathy Associated with Polyclonal Plasmacytosis in Patients Receiving Lenalidomide Maintenance Therapy. Blood, 2011, 118, 5130-5130.	1.4	7
77	Vanadium: A Panacea for Resistance to Oncolytic Immunotherapy?. Molecular Therapy, 2018, 26, 9-12.	8.2	6
78	Phase II study of enzalutamide in androgen receptor positive, recurrent, high- and low-grade serous ovarian cancer. Gynecologic Oncology, 2022, 164, 12-17.	1.4	6
79	A phase I study of concomitant galinpepimut-s (GPS) in combination with nivolumab (nivo) in patients (pts) with WT1+ ovarian cancer (OC) in second or third remission.. Journal of Clinical Oncology, 2018, 36, 5553-5553.	1.6	5
80	Treatment of ovarian clear cell carcinoma with immune checkpoint blockade: a case series. International Journal of Gynecological Cancer, 2022, , ijgc-2022-003430.	2.5	5
81	Utility of serum CA-125 monitoring in patients with ovarian cancer undergoing immune checkpoint inhibitor therapy. Gynecologic Oncology, 2020, 158, 303-308.	1.4	4
82	Pattern of disease and response to pembrolizumab in recurrent cervical cancer. Gynecologic Oncology Reports, 2021, 37, 100831.	0.6	4
83	Targeting Ribonucleotide Reductase Induces Synthetic Lethality in PP2A-Deficient Uterine Serous Carcinoma. Cancer Research, 2022, 82, 721-733.	0.9	4
84	Beyond T Cells: IgA Incites Immune Recognition in Endometrial Cancer. Cancer Research, 2022, 82, 766-768.	0.9	4
85	Virus, Vessel, Victory: A Novel Approach to Tumor Killing. Clinical Cancer Research, 2019, 25, 1446-1448.	7.0	3
86	Rejuvenating dysfunctional TÂcells in ovarian cancer: CD28 is the license to kill. Cancer Cell, 2021, 39, 1567-1569.	16.8	3
87	A phase 1 dose-escalation study of intraperitoneal cisplatin, intravenous/intraperitoneal paclitaxel, bevacizumab, and olaparib for newly diagnosed ovarian cancer. Gynecologic Oncology, 2020, 157, 214-221.	1.4	2
88	Validation of Anti-Mouse PDL-1 Goat Polyclonal Antibody Staining with Mouse PDL-1 In Situ Hybridization on Adjacent Sections of Cell Pellets and Mouse Tumors. Methods in Molecular Biology, 2017, 1554, 253-262.	0.9	2
89	Recurrent <i>WWTR1</i> <i>S89W</i> mutations and Hippo pathway deregulation in clear cell carcinomas of the cervix. Journal of Pathology, 2022, 257, 635-649.	4.5	2
90	Cancer therapy with Newcastle disease virus: rationale for new immunotherapeutic combinations. Clinical Investigation, 2015, 5, 75-87.	0.0	1

#	ARTICLE	IF	CITATIONS
91	Immunomodulatory Drugs Encoded by Oncolytic Viruses: Is the Whole Greater Than the Sum?. Molecular Therapy, 2019, 27, 1874-1877.	8.2	0
92	Abstract PO068: Distinct immune signatures predicting clinical response to PD-1 blockade therapy in gynecological cancers revealed by high-dimensional immune profiling. , 2021, , .		0
93	Challenges and Opportunities for Immunotherapy in Gynecologic Cancer. Advances in Oncology, 2021, 1, 113-123.	0.2	0
94	Standardized Uptake Value Illuminates Tumor Inflammation and Treatment Response. Clinical Cancer Research, 2021, 27, clincanres.1350.2021.	7.0	0
95	Patterns of Disease Relapse and Progression in Patients with Multiple Myeloma After First Line Therapy with Autologous Stem Cell Transplantation: Implications for Patient Monitoring After Transplantation. Blood, 2011, 118, 825-825.	1.4	0
96	Reactive Polyclonal Gammopathy Associated with Polyclonal Plasmacytosis Is Common in Patients with Multiple Myeloma Receiving Prolonged Lenalidomide Therapy: A Retrospective Study of 104 Patients. Blood, 2012, 120, 4033-4033.	1.4	0
97	Abstract CT218: First-in-human trial of intravenous MEDI9253, an oncolytic virus, in combination with durvalumab in patients with advanced solid tumors. Cancer Research, 2022, 82, CT218-CT218.	0.9	0